NEW YORK – Takeda said on Tuesday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion and recommended approval for brentuximab vedotin (Adcetris) in combination with cyclophosphamide, doxorubicin, and prednisone for adults with previously untreated CD30-positive anaplastic large cell lymphoma, or sALCL.